Quince Therapeutics, Inc. Logo

Quince Therapeutics, Inc.

Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.

QNCX | US

Overview

Corporate Details

ISIN(s):
US22053A1079
LEI:
Country:
United States of America
Address:
611 GATEWAY BLVD., SUITE 273, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing and commercializing therapeutics for rare diseases. The company's core technology is its proprietary Autologous Intracellular Drug Encapsulation (AIDE) platform, a novel drug/device combination that encapsulates drugs within a patient's own red blood cells. This delivery system is designed to improve tolerability, enhance tissue biodistribution, and reduce the adverse effects of potent medicines. Quince's lead product candidate, eDSP, is in a pivotal Phase 3 clinical trial for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved therapies. The eDSP System has received Fast Track designation from the U.S. Food and Drug Administration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Quince Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quince Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quince Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea
260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea
014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America
KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan
4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan
4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia
KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America
KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea
307750
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea
009290

Talk to a Data Expert

Have a question? We'll get back to you promptly.